undamentalytics Newsletter
Sign in

Bioage Labs, Inc. cash flow statement

In fiscal 2025, Bioage Labs, Inc.'s operations generated −$81.6m of cash; it spent $719,000 on capital projects, leaving free cash flow of −$82.3m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−52−82−88
Depreciation and amortisation00—
Stock-based pay71214
Capital spending010
Free cash flow−52−82−88
Free cash flow after stock pay−59−94−102
Shares issued017—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BIOA vs RLAYBIOA vs CRBUBIOA vs IRD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Bioage Labs, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bioage Labs, Inc.